Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Mymetics Corp

Market Cap 439K 383K 354K 332K 622K 41.4M 626K 4.2M 1.63M 20.38M 1.65M 1.61M 70.76M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.88M 58.24M 54.52M 102M 6.81B 103M 691M 268M 3.35B 271M 265M 11.63B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 18/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+1.44%-1.25%+63.52%+114.88% 55.19B
+4.60%+3.02%+58.20%+47.16% 45.75B
-1.44%+0.39%-12.94%-19.24% 22.98B
-2.69%-2.10%-3.68%+379.00% 20.76B
+3.22%-0.84%+27.88%-34.00% 16.26B
+0.58%+1.08%+16.73%-38.06% 15.42B
-1.01%-2.30%+27.42%+171.92% 13.05B
+4.95%+11.70%+123.63%+252.19% 12.45B
+3.07%+0.14%+29.37% - 12.37B
Average +0.13%+2.23%+36.68%+109.23% 23.8B
Weighted average by Cap. +1.63%+1.48%+40.92%+99.91%

Financials

2021 2022
Net sales 430K 375K 347K 325K 610K 40.57M 613K 4.12M 1.6M 19.97M 1.61M 1.58M 69.34M 1.03M 896K 830K 777K 1.46M 97M 1.47M 9.85M 3.82M 47.74M 3.86M 3.78M 166M
Net income -4.73M -4.12M -3.82M -3.58M -6.71M -446M -6.75M -45.31M -17.56M -220M -17.76M -17.37M -763M -4.8M -4.19M -3.88M -3.63M -6.81M -453M -6.85M -46.03M -17.84M -223M -18.04M -17.65M -775M
Net Debt 67.1M 58.5M 54.18M 50.72M 95.13M 6.33B 95.7M 643M 249M 3.12B 252M 246M 10.82B 71.68M 62.5M 57.89M 54.19M 102M 6.76B 102M 687M 266M 3.33B 269M 263M 11.56B
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!